

AD_____

Award Number: W81XWH-04-1-0255

TITLE: Origin and Properties of Prostatic Stem Cells

PRINCIPAL INVESTIGATOR: Elaine L. Wilson, Ph.D.

CONTRACTING ORGANIZATION: New York University School of Medicine
New York, New York 10016

REPORT DATE: February 2005

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20050603 142

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE February 2005	3. REPORT TYPE AND DATES COVERED Annual (21 Jan 2004 - 20 Jan 2005)	
4. TITLE AND SUBTITLE Origin and Properties of Prostatic Stem Cells			5. FUNDING NUMBERS W81XWH-04-1-0255	
6. AUTHOR(S) Elaine L. Wilson, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) New York University School of Medicine New York, New York 10016 E-Mail: Wilson01@endeavor.med.nyu.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) The aim of this proposal is to isolate and characterize prostatic epithelial stem cells. This will be done as stem cell and tumor cell biology may be closely linked and stem cells may have a role in the etiology of cancer. Stem cells and tumor cells have many common features including self-renewal, multi-drug resistance, telomerase expression and, in the instance of the prostate, androgen independence. Stem cells from a variety of tissues have been shown to actively efflux the Hoechst dye 33342 through the activity of multi-drugresistance-like proteins and this property has been used to characterize and isolate them as a side population (SP). Our results show that the dorsal prostate contains a small population of cells (0.65%) capable of effluxing the Hoechst dye by an active process (the side population), indicating that cells with features of stem cells are found in the prostate. In addition we show that 96% of the SP cells express Sca-1, a protein expressed by stem cells of other origins. Most of the Sca-1 expressing cells also express α 6 integrin which is also found on many primitive cell types. We also show that SP cells have a greater proliferative capacity than non-SP cells as expected if SP cells are of more primitive origin than non-SP cells.				
14. SUBJECT TERMS Prostate stem cells, fluorescent activated cell sorting for stem cells and cell surface protein, bone marrow stem cells				15. NUMBER OF PAGES 9
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1.....
SF 298.....	2.....
Introduction.....	4.....
Body.....	4 - 7.....
Key Research Accomplishments.....	7.....
Reportable Outcomes.....	7.....
Conclusions.....	8.....
References.....	8 - 9.....

Introduction

The aim of this proposal is to isolate and characterize prostatic epithelial stem cells. This will be done as stem cell and tumor cell biology may be closely linked and stem cells may have a role in the etiology of cancer [1-4]. Stem cells and tumor cells have many common features including self-renewal, multi-drug resistance, telomerase expression and, in the instance of the prostate, androgen independence. Stem cells from a variety of tissues have been shown to actively efflux the Hoechst dye [5] through the activity of multi-drug-resistance (MDR)-like proteins [6] and this property has been used to characterize and isolate them as a side population (SP).

There is also a compelling body of evidence that indicates that adult bone marrow (BM)-derived stem cells are able to differentiate into numerous types of tissues [7]. Recent evidence also indicates that gastric cancer can originate from BM-derived cells [8]. This data indicates that BM gives rise not only to normal differentiated cells in a variety of organs but that BM cells are also capable of being transformed within an organ and form tumors.

The aim of this proposal is to determine if cells with properties expressed by side population cells are located in the prostatic tissue of mice, to examine these cells for the expression of marker proteins and to determine if they have growth properties of stem cells. In addition we will determine if BM cells are able to 'home' to prostate and differentiate into tissues of the urogenital tract.

Body

Tasks 1 and 2. To identify and isolate the side population (SP) of Hoechst-effluxing cells from the dorsal prostate (DP) and to identify the proteins expressed in SP cells.

A considerable amount of time and effort was expended in determining the correct conditions for obtaining and isolating a viable SP from mouse prostate. SP cells are able to efflux the Hoechst dye via a MDR-like transporter protein which is an active biological process. Verapamil (50 μ M) was added to some tubes to verify the presence of a SP capable of pumping out the Hoechst dye as it inhibits the activity of MDR-like proteins. We found that verapamil addition prevented the appearance of SP cells indicating that this was an active process. The Hoechst concentration, staining time and temperature are critical for obtaining cells with SP properties that are viable. Different tissues require different conditions of labeling and the time of incubation with the Hoechst dye was varied to determination the best conditions for identifying and isolating the SP. As the Hoechst dye is toxic to cells and as viable cells are required for our in vitro studies we determined the conditions that gave us the best SP with the least toxicity. Propidium iodide (PI) at 2 μ g/ml was added to the cells to identify dead cells as dead cells take up this dye.

Mouse dorsal prostate tissue was digested in collagenase (0.5 mg/ml) for 2 hour followed by digestion in 0.25% trypsin for 10 minutes. We determined that the optimum

conditions for revealing a viable SP in prostate cell digests resulted from incubating cells in Hoechst 33342 (5 μ g/ml) for 90 minutes at 37°C. SP cells were evident in the proximal and in the remaining regions of prostates ducts. We also examined the SP for evidence of two proteins known to be expressed by primitive cells - α 6 integrin and Sca-1.

The results of a SP experiment are shown in Fig. 1. In order to obtain valid data a considerable number of cells need to be examined as the SP is such a small population. Propidium iodide was added before FACS analysis to eliminate dead cells from the study. After Hoechst incubation 40% of the cells were viable. Fig. 1A shows the side scatter (SSC) and forward scatter (FCS) properties (i.e., the size and granularity of the cells) of the viable Hoechst treated cell population. Fig. 1B shows the Hoechst excluding SP (R2) is 0.65% of the viable population (R1) (1036 SP cells from 159,679 viable cells in R1). The expression of α 6 integrin and Sca-1 was determined on these cells after incubating the Hoechst treated cells with either PE-labeled (Sca-1) or FITC-labeled (α 6 integrin) antibodies to these antigens. Isoyptpe matched control antibodies were added to some cells as controls (Fig. 1C). Fig. 1D indicates that 87.9% of the cells in the SP expressed both Sca-1 and α 6 integrin whereas 8.1% of SP cells expressed Sca-1 only. We have previously shown that the proximal region of mouse prostatic ducts (which contains the cells with greatest proliferative potential [9]) is enriched in Sca-1 expressing cells. We next examined the SSC and FSC properties of the SP to determine the sizes and granularity of these cells and found that the SP is comprised of cells that are small to medium sized with little granularity (Fig. 1E).

These results show that the dorsal prostate contains cells capable of effluxing the Hoechst 33342 dye by an active process (the side population), indicating that cells with features of stem cells are found in the prostate gland. In addition we show that 96% of the SP cells express Sca-1, a protein shown to be expressed by stem cells of other origins [10, 11]. Most of the Sca-1 expressing cells also express α 6 integrin which is also found on many primitive cell types [12-14].

Task 3. To determine the growth potential of SP and non-SP cells

We next examined the growth properties of the FACS sorted SP cells by suspending them in collagen gels and determining the numbers and sizes of prostatic ducts formed after 2 weeks incubation at 37°C. We have previously found that primitive prostatic cells have an increased duct-forming efficiency and also form larger and more complex ducts [9]. We found that SP cells formed 21.3 ± 3.8 ducts compared with 6.3 ± 0.6 ducts for non-SP cells ($p < 0.001$; Fig. 2A). The sizes and complexity of the ducts formed from SP cells was also greater than those of non-SP cells (Fig. 2B, C).

These data indicate that SP cells have a greater proliferative capacity than non-SP cells as would be expected if SP cells are of more primitive origin than non-SP cells.




Fig. 1. Dorsal prostate contains SP cells that express Sca-1 and α 6 integrin.
A. SSC and FCS properties of the viable Hoechst stained population.
B. Viable SP cells represent 0.65% of the total population. **C.** Hoechst stained cells were incubated with isotype-matched control PE and FITC labeled antibodies. **D.** SP cells express both Sca-1 and α 6 integrin. **E.** SSC and FCS properties of the SP cells.




Fig 2. SP cells have greater proliferative potential than non-SP cells.
A. FACS sorted SP and non-SP cells (4000/well) were seeded in collagen gels and the numbers and sizes of ducts were determined after 14 days.
B and C. SP cells (B) formed larger and more complex structures in collagen gels than non-SP cells (C).

Key research accomplishments

- 1) Conditions for obtaining a Hoechst 33342 dye excluding population of viable prostate stem cells (a side population of prostatic stem cells) have been defined.
- 2) The prostate SP also expresses two antigens found on stem cells of other origins, namely Sca-1 and $\alpha 6$ integrin.
- 3) SP cells have greater proliferative potential than non-SP cells in collagen gel assays designed to measure the numbers and sizes of prostatic ducts that arise from individual cells.

Reportable outcomes

We have developed conditions that result in the ability to obtain a viable FACS sorted population of SP from the dorsal prostate of the mouse. This will enable investigators in the field to isolate and study this population of stem/progenitor cells.

Results of these studies will be presented at an NIH meeting on stem cell niches in May 2005.

Conclusions

We have identified a population of prostatic cells capable of effluxing the Hoechst 33342 dye, through an active process. These cells represent 0.65% of the prostatic cell population and are identified as a side population (SP) using FACS analysis. SP cells haven shown to identify a stem cell population in other organs. The prostatic SP cells have greater growth potential in vitro than non-SP cells indicating that they are of a more primitive nature than non-SP cells.

We believe that prostate stem cells and tumor cells are closely linked and expect that prostate tumor cells will have a similar phenotype to normal prostate stem cells. Prostate carcinoma usually progresses to an androgen-independent tumor that may reflect a stem cell-like phenotype. The isolation and elucidation of the phenotype of prostate stem cells is therefore likely to increase our understanding not only of normal prostate physiology but also of prostate carcinoma. The identification of prostate stem cells may also permit the development of new rational therapies to treat prostate carcinoma based on a stem cell phenotype. As normal prostate stem cells and indeed the presence of a prostate are not essential to health, the ablation of normal prostate cells in conjunction with carcinoma cells would have no adverse effects on the patient. Our goal is to elucidate the phenotype of normal prostate stem cells and apply what we learn to prostate carcinoma with the aim of developing new therapies to treat this disease.

Personnel supported by this grant

E Lynette Wilson PI Effort 15%

Sandra Coetzee Research Associate Effort 100% On grant until 30 November 2004

Rashmi Gupta Postdoctoral Fellow Effort 100% On grant as from 1 January 2005

References

1. Reya, T., S.J. Morrison, M.F. Clarke, and I.L. Weissman. *Stem cells, cancer, and cancer stem cells*. Nature, 2001. **414**(6859): p. 105-111.
2. Al-Hajj, M., M.S. Wicha, A. Benito-Hernandez, S.J. Morrison, and M.F. Clarke. *Prospective identification of tumorigenic breast cancer cells*. Proc Natl Acad Sci U S A, 2003. **100**(7): p. 3983-8.
3. Al-Hajj, M. and M.F. Clarke. *Self-renewal and solid tumor stem cells*. Oncogene, 2004. **23**(43): p. 7274-82.
4. Pardal, R., M.F. Clarke, and S.J. Morrison. *Applying the principles of stem-cell biology to cancer*. Nat Rev Cancer, 2003. **3**(12): p. 895-902.
5. Goodell, M.A. *Multipotential stem cells and 'side population' cells*. Cytotherapy, 2002. **4**(6): p. 507-8.

6. Zhou, S., J.D. Schuetz, K.D. Bunting, A.M. Colapietro, J. Sampath, J.J. Morris, I. Lagutina, G.C. Grosveld, M. Osawa, H. Nakauchi, and B.P. Sorrentino. *The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype*. Nat Med, 2001. **7**(9): p. 1028-34.
7. Krause, D.S., N.D. Theise, M.I. Collector, O. Henegariu, S. Hwang, R. Gardner, S. Neutzel, and S.J. Sharkis. *Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell*. Cell, 2001. **105**(3): p. 369-77.
8. Houghton, J., C. Stoicov, S. Nomura, A.B. Rogers, J. Carlson, H. Li, X. Cai, J.G. Fox, J.R. Goldenring, and T.C. Wang. *Gastric cancer originating from bone marrow-derived cells*. Science, 2004. **306**(5701): p. 1568-71.
9. Tsujimura, A., Y. Koikawa, S. Salm, T. Takao, S. Coetzee, D. Moscatelli, E. Shapiro, H. Lepor, T.T. Sun, and E.L. Wilson. *Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis*. J Cell Biol, 2002. **157**(7): p. 1257-65.
10. Jackson, K.A., S.M. Majka, G.G. Wulf, and M.A. Goodell. *Stem cells: a minireview*. J Cell Biochem Suppl, 2002. **38**: p. 1-6.
11. Welm, B.E., S.B. Tepera, T. Venezia, T.A. Graubert, J.M. Rosen, and M.A. Goodell. *Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population*. Dev Biol, 2002. **245**(1): p. 42-56.
12. Suzuki, A., Y. Zheng, R. Kondo, M. Kusakabe, Y. Takada, K. Fukao, H. Nakauchi, and H. Taniguchi. *Flow-cytometric separation and enrichment of hepatic progenitor cells in the developing mouse liver*. Hepatology, 2000. **32**(6): p. 1230-9.
13. Tani, H., R.J. Morris, and P. Kaur. *Enrichment for murine keratinocyte stem cells based on cell surface phenotype*. Proc Natl Acad Sci U S A, 2000. **97**(20): p. 10960-5.
14. Shinohara, T., M.R. Avarbock, and R.L. Brinster. *beta1- and alpha6-integrin are surface markers on mouse spermatogonial stem cells*. Proc Natl Acad Sci U S A, 1999. **96**(10): p. 5504-9.